RPRD1B anticorps
Aperçu rapide pour RPRD1B anticorps (ABIN1387232)
Antigène
Voir toutes RPRD1B AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Réactivité croisée
- Humain, Souris, Rat
-
Purification
- Purified by Protein A.
-
Immunogène
- KLH conjugated synthetic peptide derived from human CREPT
-
Isotype
- IgG
-
-
-
-
Indications d'application
-
WB 1:300-5000
IHC-P 1:200-400
IF(IHC-P) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Agent conservateur
- ProClin
-
Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Date de péremption
- 12 months
-
-
- RPRD1B (Regulation of Nuclear Pre-mRNA Domain Containing 1B (RPRD1B))
-
Autre désignation
- CREPT
-
Sujet
-
Synonyms: C20orf77, Cell cycle related and expression elevated protein in tumor, Chromosome 20 open reading frame 77, CREPT, dJ1057B20.2, DKFZp434P0735, FLJ44520, Hypothetical protein LOC58490, Uncharacterized protein C20orf77, RPR1B_HUMAN.
Background: Interacts with phosphorylated C-terminal heptapeptiderepeat domain (CTD) of the largest RNA polymerase II subunitPOLR2A, and participates in dephosphorylation of the CTD.Transcriptional regulator which enhances expression of CCND1.Promotes binding of RNA polymerase II to the CCDN1 promoter and tothe termination region before the poly-A site but decreases itsbinding after the poly-A site. Prevents RNA polymerase II fromreading through the 3' end termination site and may allow it to berecruited back to the promoter through promotion of the formationof a chromatin loop. Also enhances the transcription of a number ofother cell cycle-related genes including CDK2, CDK4, CDK6 andcyclin-E but not CDKN1A, CDKN1B or cyclin-A. Promotes cell proliferation.
Antigène
-